Professor Marco Gerlinger
Group Leader
Jump to Section
Professor of Gastrointestinal Cancer Medicine
Consultant Medical Oncologist and Director of GI Cancer Research at St. Bartholomew's Hospital
Overview
We are investigating how drug resistance evolves in bowel and gastro-oesophageal cancers, how these tumour types can be treated more effectively through novel immunotherapies and targeted drugs, and how treatment sensitivity and resistance can be predicted. Our research insights have already informed several clinical trials that test new therapies in early-stage and metastatic colorectal and gastro-oesophageal cancers.
Team
Dr Louise Barber
Senior Scientific Officer
Dr Lucas Baumard
Postdoctoral Researcher
Mennatallah Ghouraba
PhD Student
Thaneswari Karpanasamy
PhD Student
Yuliia Kravchuk
Technician
Dr Rosemary Lane
Postdoctoral Researcher
Dr Neil McCafferty
Bioinformatician
Sarah Penny
Postdoctoral Researcher
Thomas Savy
PhD Student
Dr Lucy Stevens
Clinical Research Fellow
Key Publications
Extreme intratumour heterogeneity and driver evolution in mismatch repair deficient gastro-oesophageal cancer. Nat Commun (2020) 11(1):139. PMID: 31949146
Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment. J Immunother Cancer (2019) 7(1):309. PMID: 31735170
Genomic and transcriptomic determinants of therapy resistance and immune landscape evolution during anti-EGFR treatment in colorectal cancer. Cancer Cell (2019) 36(1):35-50.e9. PMID: 31287991
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 366(10):883-892. PMID: 22397650
See recent publicationsMajor Funding
- 2019-2024- European Research Council (ERC), Deciphering and predicting the evolution of cancer cell populations, EUR 2 Mio
Related News
In conversation with Professor Marco Gerlinger
This International Clinical Trials Day, we spoke with Professor Marco Gerlinger. Professor Gerlinger and his team’s laboratory research focuses on understanding and overcoming drug resistance in bowel and gastro-oesophageal cancers, and identifying new and more effective ways to treat these cancers using immunotherapies and combination therapies.
General News 20 May 2022